share email twitter ⋅ join discord whatsapp(2ck)
free120  nbme24  nbme23  nbme22  nbme21  nbme20  nbme19  nbme18  nbme17  nbme16  nbme15  nbme13 

NBME Answers

free120/Block 3/Question#15 (15.7 difficulty score)
A 46-year-old woman with active ankylosing ...
Tumor necrosis factor α🔍

Login to comment/vote.

submitted by em_goldman(22),

Rituximab (anti-CD 20) is currently undergoing trials for AS. My sparse googling just now shows that rituximab probably only has a moderate effect, so probably second-line to anti-TNFa therapy. Probably.

Safe to say for boards that AS: TNFa > CD20

cheesetouch  FA 2018 - rituximab p 430 -- - use for Nonhodgkins lymphoma, CLL, ITP, Rheumatoid arthritis TNF-a inhibitors - p 472: 1) etanercept for Ra, psoriasis, ankylosing spondylitis. 2) infliximab and other mAB for IBD, RA, AS, psoriasis +1  

submitted by osler_weber_rendu(86),

Monoclonal Antibodies are always last resort! I just use this as a general rule

submitted by benwhite_dotcom(465),
unscramble the site ⋅ remove ads ⋅ become a member ($39/month)

yMan mttnyaoenuiuotamr/fulimoama ciin,tdnoso uldnignci olnynikgas ssytliiodpn, ear ttarede tiwh RDsMAD ikel hanaFNat-iTp-l aniiemcdots wnhe demrli sfutf edo’stn do eth .crkit oCommn asmxeelp rae aiiilmxbnf dcmei)(Rae adn lmbaumiaad r(ua.Hmi)